Filing Flows › Akebia Therapeutics (AKBA) › Q2 2025
Akebia Therapeutics (AKBA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Akebia Therapeutics (AKBA) reported revenue of $62.5M for the second quarter 2025 (Q2 2025), +43% from a year earlier and +9% from the quarter before. Operating margin was 22.6%, net earnings $247K (0.4% of revenue).
Akebia Therapeutics, Q2 2025: revenue $62.5M (+43% year over year), operating margin 22.6%, net earnings $247K, operating cash flow $22.3M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $62.5M | +9% | +43% |
| Operating profit | $14.1M | +4% | — |
| Net earnings | $247K | -96% | — |
| Operating cash flow | $22.3M | — | — |
| Free cash flow | $22.2M | — | — |
What changed
Revenue was $62.5M in Q2 2025, up 43% year over year and up 9% from the previous quarter. Auryxia was the largest line at 76% of revenue. Auryxia added $6.0M year over year (up 14%), 32% of the total change. License, collaboration and other revenue declined 18%.
Operating profit was $14.1M, a 22.6% margin (up 42.5 points year over year). Total costs fell 8% while revenue rose 43%. The fastest-growing cost line was Research & development (+44%). Net earnings were $247K. The effective tax rate was 0.0%.
Operating cash flow was $22.3M, 9047% of net earnings. Non-cash charges added back $316K of depreciation and amortization and $2.7M of share-based compensation. Working capital and other items added $19.1M. Capital expenditures of $126K left free cash flow of $22.2M.
Questions
What was Akebia Therapeutics' revenue in the second quarter 2025?
Akebia Therapeutics (AKBA) reported revenue of $62.5M for the second quarter 2025 (Q2 2025), +43% from a year earlier and +9% from the quarter before.
Was Akebia Therapeutics profitable in the second quarter 2025?
Operating profit was $14.1M (22.6% of revenue) and net earnings $247K.